

## Special Issue

# Cancer Cell Communications, Metastasis and Survival in Host Microenvironment

### Message from the Guest Editor

Cancer metastasis is responsible for approximately 90% cancer death [1]. When an invading cancer cell migrates out of the primary solid tumor, this cell faces unfriendly host cells in the microenvironment [2,3]. WW domain-containing oxidoreductase (WWOX)-deficient or -dysfunctional cancer cells, designated WWOXd [2,3], are mainly metastatic, and cannot recognize host cells and parental cancer cells. These metastatic cancer cells are able to dodge, compromise, and cause damage to the WWOX-functional normal host cells or parental cancer cells (WWOXf) from a distance [2,3]. WWOXf cells are either normal cells or benign cancer cells [2,3]. In this call for research and review papers 2023, the specific topic will focus on gene alterations that contribute to changes in cancer cell migratory behavior, cell-to-cell recognition and communication, cancer cell-host cell functional antagonism, and cell survival in host microenvironment.

---

### Guest Editor

Dr. Nan-Shan Chang

Graduate Institute of Biomedical Sciences, College of Medicine, China Medical University, Taichung 40402, Taiwan

---

### Deadline for manuscript submissions

closed (31 December 2024)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/si/206253](https://mdpi.com/si/206253)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)